Comparative neurofilament light chain trajectories in CSF and plasma in autosomal dominant Alzheimer's disease.

ABSTRACT: Disease-modifying therapies for Alzheimer's disease (AD) are likely to be most beneficial when initiated in the presymptomatic phase. To track the benefit of such interventions, fluid biomarkers are of great importance, with neurofilament light chain protein (NfL) showing promise for monitoring neurodegeneration and predicting cognitive outcomes. Here, we update and complement previous findings from the Dominantly Inherited Alzheimer Network Observational Study by using matched cross-sectional and longitudinal cerebrospinal fluid (CSF) and plasma samples from 567 individuals, allowing timely comparative analyses of CSF and blood trajectories across the entire disease spectrum. CSF and plasma trajectories were similar at presymptomatic stages, discriminating mutation carriers from non-carri

SUBMITTER: Hofmann A 

PROVIDER: S-EPMC11574007 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature